Therefore, an agent that blocks BAFF could be a second biologic (Fig. 3B) in diseases in which B cells are thought to contribute, such as systemic lupus erythematosus (Thien et al., 2004; Cancro et al., 2009; Navarra et al., 2011). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.